-
Marked IDO2 expression and activity related to autophagy and apoptosis in brain tissue of fatal tuberculous meningitis Tuberculosis (IF 3.2) Pub Date : 2024-03-06 Lihui Guo, Stefan-Dan Zaharie, A. Marceline van Furth, Nicole N. van der Wel, Anita E. Grootemaat, Lin Zhang, Marianna Bugiani, Mariana Kruger, Martijn van der Kuip, René Lutter
In about 1% of tuberculosis (TB) patients, () can disseminate to the meninges, causing tuberculous meningitis (TBM) with mortality rate up to 60%.
-
Role of MicroRNAs as post transcription regulators of matrix metalloproteinases and their association in tuberculous meningitis Tuberculosis (IF 3.2) Pub Date : 2024-03-05 Apoorva Aggarwal, Neeraj Singla, Monidipa Konar, Maninder Kaur, Kusum Sharma, Kajal Jain, Manish Modi, Sadhna Sharma
Matrix metalloproteinases (MMPs) have a role in driving neuroinflammation in infectious as well as non-infectious diseases; however, recent reports have potentiated the role of microRNAs in regulating MMPs at post-transcriptional levels, leading to dysregulation of crucial MMP functions like tissue remodelling, blood brain barrier integrity, etc. In present study, microRNAs regulating MMPs (MMP2 and
-
METTL3-deficiency m6A-dependently degrades MALAT1 to suppress NLRP3-mediated pyroptotic cell death and inflammation in Mycobacterium tuberculosis (H37Ra strain)-infected mouse macrophages Tuberculosis (IF 3.2) Pub Date : 2024-03-04 Limei Han, Nueramina Tieliwaerdi, Xin Li
(Mtb)-infected macrophages aggravated the development of pulmonary tuberculosis, but its detailed molecular mechanisms are still largely unknown. Here, the mouse primary peritoneal macrophages were infected with the attenuated strain of Mtb H37Ra, and we firstly verified that targeting a novel METTL3/N6-Methyladenosine (m6A)/LncRNA MALAT1/miR-125b/TLR4 axis was effective to suppress pyroptotic cell
-
Trends of type 2 diabetes with pulmonary tuberculosis patients,2013–2022, and changes after the coronavirus disease 2019 (COVID-19) pandemic Tuberculosis (IF 3.2) Pub Date : 2024-02-27 Zijian Wang, Sheng Zhao, Aiping Zhang, Bin Quan, Chun Duan, Manman Liang, Janghua Yang
To describe the trends of Type 2 Diabetes with Pulmonary Tuberculosis (T2DM-TB) patients from 2013 to 2022 and to investigate the impact of COVID-19 lockdown on glycemic control and associated factors in T2DM-TB. In this population-based study of the First Affiliated Yijishan Hospital of Wannan Medical College in China, we described the 10-year trends of patients diagnosed with T2DM-TB. We included
-
Computational drug repositioning identifies niclosamide and tribromsalan as inhibitors of Mycobacterium tuberculosis and Mycobacterium abscessus Tuberculosis (IF 3.2) Pub Date : 2024-02-27 Jeremy J. Yang, Aaron Goff, David J. Wild, Ying Ding, Ayano Annis, Randy Kerber, Brian Foote, Anurag Passi, Joel L. Duerksen, Shelley London, Ana C. Puhl, Thomas R. Lane, Miriam Braunstein, Simon J. Waddell, Sean Ekins
Tuberculosis (TB) is still a major global health challenge, killing over 1.5 million people each year, and hence, there is a need to identify and develop novel treatments for (). The prevalence of infections caused by nontuberculous mycobacteria (NTM) is also increasing and has overtaken TB cases in the United States and much of the developed world. is one of the most frequently encountered NTM and
-
Lysosomal enzymes and the oxygen burst capability of monocyte-derived macrophages in active drug-resistant tuberculosis patients in relation to cell attachment Tuberculosis (IF 3.2) Pub Date : 2024-02-24 Febriana Catur Iswanti, Kurnia Maidarmi Handayani, Ardiana Kusumaningrum, Tomohiko Yamazaki, Diah Handayani, Mohamad Sadikin
Drug resistance to tuberculosis (TB) has become an obstacle in eliminating tuberculosis. The transmission of drug-resistant TB from patients increases the incidence of primary drug-resistant (DR) TB in individuals who are in close contact. Therefore, it is necessary to incorporate an immunological approach into preventive therapy. This study focuses on the activity of lysosomal enzymes, oxygen bursts
-
Analysis of T-lymphocyte subsets and risk factors in children with tuberculosis Tuberculosis (IF 3.2) Pub Date : 2024-02-20 Wei-Wei Ma, Ling-Chao Wang, De-An Zhao, Na Wei, Jun-Wei Cui, Shu-Jun Li
Tuberculosis (TB) is not only related to infection but also involves immune factors. This study explores the changes in T-lymphocyte subsets in children with TB who are human immunodeficiency virus (HIV)-negative and examines their relationship using chest computed tomography (CT) scans. Additionally, the study identifies risk factors for severe TB (STB) in children and establishes relevant risk prediction
-
Steroid immune responsive gene regulation in Mycobacterium tuberculosis infection in vitro Tuberculosis (IF 3.2) Pub Date : 2024-02-20 Maria Eduarda de Albuquerque Borborema, Débora Elienai de Oliveira Miranda, Thays Maria Costa de Lucena, Virgínia Maria Barros de Lorena, Michelle Christiane da Silva Rabello, Jaqueline de Azevêdo Silva
Tuberculosis (TB) is an infectious disease displaying a multifactorial pathology. The immunomodulatory role attributed to steroid hormones, such as vitamin D (VD) and 17β-estradiol (E), highlighted the importance of these hormones against () infection. In order to understand their influence upon gene expression of immune and inflammatory responsive genes against we tested it using peripheral blood
-
Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains Tuberculosis (IF 3.2) Pub Date : 2024-02-13 Hannah Painter, Sam Willcocks, Andrea Zelmer, Rajko Reljic, Rachel Tanner, Helen Fletcher
Human tuberculosis (TB) is caused by various members of the (Mtb) complex. Differences in host response to infection have been reported, illustrative of a need to evaluate efficacy of novel vaccine candidates against multiple strains in preclinical studies. We previously showed that the murine lung and spleen direct mycobacterial growth inhibition assay (MGIA) can be used to assess control of mycobacterial
-
Transmission of drug-resistant Mycobacterium tuberculosis isolates between Finnish- and foreign-born cases, 2014–2021: A molecular epidemiological study Tuberculosis (IF 3.2) Pub Date : 2024-02-12 Jiahui Zhu, Marjo Haanpera, Silja Mentula, Olli Vapalahti, Hanna Soini, Tarja Sironen, Ravi Kant, Fathiah Zakham
Data on the molecular epidemiology and transmission of drug-resistant (MTB) in low-incidence settings with immigration from high-incidence settings is limited. We included 115 drug-resistant (DR) MTB isolates with whole-genome sequencing data isolated in Finland between 2014 and 2021. Potential transmission clusters were identified using a threshold of 12 single-nucleotide polymorphisms (SNPs). Highly
-
Caveolin-1 affects early mycobacterial infection and apoptosis in macrophages and mice Tuberculosis (IF 3.2) Pub Date : 2024-02-12 Yuqing Wu, Andrea Riehle, Barbara Pollmeier, Stephanie Kadow, Fabian Schumacher, Marek Drab, Burkhard Kleuser, Erich Gulbins, Heike Grassmé
Tuberculosis, caused by , remains one of the deadliest infections in humans. Because Mycobacterium bovis Bacillus Calmette-Guérin (BCG) share genetic similarities with , it is often used as a model to elucidate the molecular mechanisms of more severe tuberculosis infection. Caveolin-1 has been implied in many physiological processes and diseases, but it's role in mycobacterial infections has barely
-
Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease Tuberculosis (IF 3.2) Pub Date : 2024-02-09 Binayak Rimal, Chandra M. Panthi, Yi Xie, Daniel C. Belz, Elisa H. Ignatius, Christopher K. Lippincott, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane
( also known as ) causes opportunistic pulmonary and soft tissue infections that are difficult to cure with existing treatments. Omadacycline, a new tetracycline antibiotic, exhibits potent and activity against . As regimens containing multiple antibiotics are required to produce a durable cure for disease, we assessed efficacies of three three-drug combinations in a pre-clinical mouse model of pulmonary
-
-
Corrigendum to “Quantitative proteomics reveals plasma protein profile and potential pathways in pulmonary tuberculosis patients with and without diabetes” [Tuberculosis 143 (2023) 102424] Tuberculosis (IF 3.2) Pub Date : 2024-02-02 Xinxin He, Yunguang Wang, Yue Yang, Qiang He, Lifang Sun, Juan Jin
Abstract not available
-
Diagnosing osteoarticular tuberculosis and detecting rifampicin resistance: A comparative analysis of Truenat MTB Plus vs GeneXpert Ultra Tuberculosis (IF 3.2) Pub Date : 2024-02-02 Kusum Sharma, Megha Sharma, Aman Sharma, Mandeep Singh Dhillon
Diagnosing osteoarticular tuberculosis (OATB) and detecting drug resistance is a challenge in an endemic country like India. Truenat MTB Plus assay (TruPlus), a chip-based portable machine, was compared with GeneXpert Ultra (GxUltra) for diagnosing drug-resistant OATB. 115 synovial fluid and pus specimens [22 culture-positive confirmed, 58 culture-negative clinically-suspected, 35 non-TB controls]
-
Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants Tuberculosis (IF 3.2) Pub Date : 2024-01-23 Zian Zhang, Lifa Xu, Xiaochun Wang, LingYun Kong, Zilun Shi, Qiangsen Zhong, Yun Xu, Jianghong Wang
Tuberculosis (TB) today remains the leading cause of global deaths due to infectious bacterial pathogens. The Bacillus Calmette-Guérin (BCG) vaccine is the only vaccine clinically used to prevent TB. However, its limitations in preventing latent infection and TB reactivation mean that it does not provide comprehensive protection. In this study, we successfully constructed and expressed the multistage
-
The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters Tuberculosis (IF 3.2) Pub Date : 2024-01-18 Neetu Kumari, Romil Sharma, Juned Ali, Gyan Chandra, Sarika Singh, Manju Y. Krishnan
Persistence of Mycobacterium tuberculosis (Mtb) is one of the challenges to successful treatment of tuberculosis (TB). In vitro models of non-replicating Mtb are used to test the efficacy of new molecules against Mtb persisters. The H37Ra strain is attenuated for growth in macrophages and mice. We validated H37Ra-infected immunocompetent mice for testing anti-TB molecules against slow/non-replicating
-
Xpert MTB/RIF Ultra for the rapid diagnosis of extrapulmonary tuberculosis in a clinical setting of high tuberculosis prevalence country and interpretation of ‘trace’ results Tuberculosis (IF 3.2) Pub Date : 2024-01-08 Rumana Nasrin, Mohammad Khaja Mafij Uddin, Sk Nazmul Kabir, Tanjina Rahman, Samanta Biswas, Aazia Hossain, S.M. Mazidur Rahman, Shahriar Ahmed, Stephane Pouzol, Jonathan Hoffmann, Sayera Banu
To evaluate the diagnostic performance of Xpert MTB/RIF Ultra (Ultra) for the diagnosis of extrapulmonary tuberculosis (EPTB) from different types of extrapulmonary specimens in comparison with culture and composite microbiological reference standard (CRS). A total of 240 specimens were prospectively collected from presumptive EPTB patients between July 2021–January 2022 and tested by Ultra, Xpert
-
Rv0495c regulates redox homeostasis in Mycobacterium tuberculosis Tuberculosis (IF 3.2) Pub Date : 2024-01-06 Rahul Pal, Sakshi Talwar, Manitosh Pandey, Vaibhav Kumar Nain, Taruna Sharma, Shaifali Tyagi, Vishawjeet Barik, Shweta Chaudhary, Sonu Kumar Gupta, Yashwant Kumar, Ranjan Nanda, Amit Singhal, Amit Kumar Pandey
-
-
Isoniazid exposures and acetylator status in Indonesian tuberculous meningitis patients Tuberculosis (IF 3.2) Pub Date : 2023-12-21 Vycke Yunivita, Lindsey te Brake, Sofiati Dian, Ahmad Rizal Ganiem, Reinout van Crevel, Rovina Ruslami, Rob Aarnoutse
The effect of acetylator status on the exposure to isoniazid in plasma and CSF in tuberculous meningitis (TBM) patients remains largely unexplored. Here, we describe isoniazid exposures and acetylator status of 48 subjects in the ReDEFINe study (NCT02169882). Fifty percentwere fast (half-life <130 min) or slow (half-life >130 min) acetylators. Slow acetylators had higher AUC0-24, Cmax and CSF concentrations
-
Antibody response to mycobacterial Rpf B protein and its immunodominant peptides in HIV-TB co-infected individuals Tuberculosis (IF 3.2) Pub Date : 2023-12-16 Madhur Kalyan, Sumedha Sharma, Prabhdeep Kaur, Aman Sharma, Indu Verma
Diagnosis of TB at early stages of HIV infection may lead to timely intervention for improving patient outcome. Antibodies to Mycobacterium tuberculosis recombinant RpfB protein and two immunodominant peptides of Rpf B protein were evaluated in the sera of HIV +TB+, HIV+ and HIV− pulmonary TB patients by ELISA. Serum antibodies from 90 % and 65 % of HIV+TB+ patients reacted to recombinant RpfB protein
-
mRNA profiling of cytokines to understand paradoxical response in HIV-uninfected tuberculous meningitis Tuberculosis (IF 3.2) Pub Date : 2023-12-09 Jayantee Kalita, Ruchi Shukla, Prakash C. Pandey, Vivek Singh, Rudrashish Haldar, Usha K. Misra
Paradoxical reaction (PR) in tuberculous meningitis (TBM) is a major management issue. We report mRNA profiling of cytokines to understand PR in HIV-uninfected TBM patients. 72 patients with TBM were included, and their clinical, MRI, and mRNA profiling of tumor necrosis factor (TNF) α, interleukin (IL) 6, IL10 and interferon (IFN) γ genes in the peripheral blood mononuclear cells were done at admission
-
Integrative and comparative genomic analyses of mammalian macrophage responses to intracellular mycobacterial pathogens Tuberculosis (IF 3.2) Pub Date : 2023-12-02 Thomas J. Hall, Gillian P. McHugo, Michael P. Mullen, James A. Ward, Kate E. Killick, John A. Browne, Stephen V. Gordon, David E. MacHugh
Mycobacterium tuberculosis, the causative agent of human tuberculosis (hTB), is a close evolutionary relative of Mycobacterium bovis, which causes bovine tuberculosis (bTB), one of the most damaging infectious diseases to livestock agriculture. Previous studies have shown that the pathogenesis of bTB disease is comparable to hTB disease, and that the bovine and human alveolar macrophage (bAM and hAM
-
Proteome and immunogenicity differences in BCG Pasteur ATCC 35734 and its derivative, the vaccine candidate BCGΔBCG1419c during planktonic growth in 7H9 and Proskauer Beck media Tuberculosis (IF 3.2) Pub Date : 2023-11-28 Mario Alberto Flores-Valdez, Jesús Bernardino Velázquez-Fernández, César Pedroza-Roldán, Michel de Jesús Aceves-Sánchez, Abel Gutiérrez-Ortega, Wendy López-Romero, Jeannette Barba-León, Jacobo Rodríguez-Campos
Bacillus Calmette–Guèrin (BCG) remains as the only vaccine employed to prevent tuberculosis (TB) during childhood. Among factors likely contributing to the variable efficacy of BCG is the modification in its antigenic repertoire that may arise from in vitro growth conditions. Our vaccine candidate, BCGΔBCG1419c, improved protection against TB in mice and guinea pigs with bacteria grown in either 7H9
-
Combined cerebrospinal fluid metabolomic and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes in immunometabolic networks Tuberculosis (IF 3.2) Pub Date : 2023-12-02 Jeffrey Tomalka, Ashish Sharma, Alison G.C. Smith, Teona Avaliani, Mariam Gujabidze, Tinatin Bakuradze, Shorena Sabanadze, Dean P. Jones, Zaza Avaliani, Maia Kipiani, Russell R. Kempker, Jeffrey M. Collins
Much of the high mortality in tuberculosis meningitis (TBM) is attributable to excessive inflammation, making it imperative to identify targets for host-directed therapies that reduce pathologic inflammation and mortality. In this study, we investigate how cytokines and metabolites in the cerebral spinal fluid (CSF) associate with TBM at diagnosis and during TBM treatment. At diagnosis, TBM patients
-
In-vivo expressed mycobacterial transcripts as diagnostic targets for pulmonary tuberculosis Tuberculosis (IF 3.2) Pub Date : 2023-11-27 Sumedha Sharma, Ashutosh N. Aggarwal, Prabhdeep Kaur, Rakesh Yadav, Sunil Sethi, Indu Verma
The nucleic acid amplification tests (NAATs) such as Xpert MTB/RIF have transformed the TB diagnostic field by significantly increasing the case detection. However, newer improved diagnostic assays are still needed to meet the WHO targets to end TB. Present study is based on a novel approach of utilizing the in-vivo expressed specific mycobacterial transcriptomic biomarkers for the diagnosis of pulmonary
-
Hematological parameters in newly diagnosed TB patients: A systematic review and meta-analysis Tuberculosis (IF 3.2) Pub Date : 2023-11-11 Maryam Farhadian, Sobhan Veisi, Negin Farhadian, Mohammad Hossein Zamanian
Despite all efforts, tuberculosis (TB) remains one of the 10 leading causes of death worldwide. The hematopoietic system is seriously affected by TB and there is little information about the hematological profile of patients with TB. In this regard, this systematic review and meta-analysis aimed to assess hematological parameters among newly diagnosed TB patients. Relevant papers were found by searching
-
Inability of the BCG vaccine to protect mice of the H2f haplotype at advanced stages of TB infection is associated with defective CD4+ T-cell activation in spleen Tuberculosis (IF 3.2) Pub Date : 2023-11-10 Maria Korotetskaya, Polina Baikuzina, Alexander Apt
We performed studies in B10.M H2-congenic mouse strain whose H2f haplotype is associated with defective BCG vaccination efficacy against TB challenge. No difference in mortality dynamics between BCG-vaccinated and primarily infected B10.M mice was observed, whereas in B10 (H2b) congenic mice BCG vaccination significantly prolonged survival. At the early stages of infection, vaccinated mice of both
-
Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex Tuberculosis (IF 3.2) Pub Date : 2023-10-28 Bosung Park, Tae Sun Shim, Kyung-Wook Jo, Eun Jeong Won, Mi-Na Kim, Heungsup Sung
Background Amikacin is a first-line drug that must be evaluated when performing an antimycobacterial susceptibility test (AST) for Mycobacterium avium complex (MAC). However, the presence of sporadic trailing growth in MAC makes determining the precise point for reading its minimal inhibitory concentration (MIC) challenging. Methods Susceptibility was re-tested for 134 MAC clinical isolates using the
-
Necrosis, netosis, and apoptosis in pulmonary tuberculosis and type-2 diabetes mellitus. Clues from the patient's serum Tuberculosis (IF 3.2) Pub Date : 2023-10-24 Oscar Rojas-Espinosa, Alma Yolanda Arce-Mendoza, Sergio Islas-Trujillo, Antonio Muñiz-Buenrostro, Patricia Arce-Paredes, Omar Popoca-Galván, Bertha Moreno-Altamirano, Miguel Rivero Silva
Pulmonary tuberculosis (PTB) and type 2 diabetes mellitus (T2DM) are two inflammatory diseases whose pathology involves neutrophils (NEU) as key participants. Countless inflammatory elements produced at the lesion sites leak into the blood and are distributed systemically. The study aimed to investigate the effect of the serum of patients with PTB, T2DM, and PTB + T2DM on the cellular and nuclear morphology
-
Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01 Tuberculosis (IF 3.2) Pub Date : 2023-10-23 Nadia Ouaked, Marie-Ange Demoitié, Fabrice Godfroid, Marie-Cécile Mortier, Yannick Vanloubbeeck, Stéphane T. Temmerman
A new efficacious tuberculosis vaccine targeting adolescents/adults represents an urgent medical need. The M72/AS01E vaccine candidate protected half of the latently-infected adults against progression to pulmonary tuberculosis in a Phase IIb trial (NCT01755598). We report that three immunizations of mice, two weeks apart, with AS01-adjuvanted M72 induced polyfunctional, Th1-cytokine-expressing M72-specific
-
Performance of IS6110-LAMP assay for detection of Mycobacterium tuberculosis complex in blood and urine samples from patients with extrapulmonary tuberculosis Tuberculosis (IF 3.2) Pub Date : 2023-10-20 Romário Martins Araújo, Rosana de Albuquerque Montenegro, Aline dos Santos Peixoto, Letícia Leoncio de Souza Silva, Rayssa Maria Pastick Jares da Costa, Wlisses Henrique Veloso Carvalho-Silva, Danyele Costa de Mello, George Tadeu Nunes Diniz, Maria Almerice Lopes da Silva, Fábio Lopes de Melo, Lílian Maria Lapa Montenegro, Haiana Charifker Schindler
Background The diagnosis of extrapulmonary tuberculosis (EPTB) shows numerous difficulties because of non-specific symptomatology and low sensitivity of conventional methods. Loop-mediated isothermal amplification (LAMP) is a fast and low-cost technique, which can amplify under isothermal conditions an amount of target DNA copies into approximately a billion copies. Objective The present study aimed
-
Quantitative proteomics reveals plasma protein profile and potential pathways in pulmonary tuberculosis patients with and without diabetes Tuberculosis (IF 3.2) Pub Date : 2023-10-18 Xinxin He, Yunguang Wang, Yue Yang, Qiang He, Lifang Sun, Juan Jin
Background The coexistence of pulmonary tuberculosis (PTB) and diabetes mellitus (DM) has emerged as a significant global public health concern. Patients with DM are at higher risk of developing PTB, and PTB is one of the important factors that exacerbate the development of DM. However, the impact of DM on the protein profile and underlying pathways in PTB patients is unclear. Methods We systematically
-
Pulmonary tuberculosis biomarker miR-215-5p inhibits autophagosome-lysosome fusion in macrophages Tuberculosis (IF 3.2) Pub Date : 2023-10-17 Feng Deng, Peng Xu, Jiahong Miao, Cheng Jin, Huihui Tu, Jianhua Zhang
The normal autophagy flux is beneficial for the rapid elimination of phagocytic pathogens by macrophages. However, Mycobacterium tuberculosis interferes with the autophagy flux of macrophages to weaken their immune function and evade immune surveillance. In this study, we found that miRNA-215-5p was downregulated in tuberculosis patients. A potential diagnostic model for tuberculosis was established
-
The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations Tuberculosis (IF 3.2) Pub Date : 2023-10-08 Dan Luo, Chong-Yu Shi, Nian-Sa Wei, Bo-Yi Yang, Kai Qin, Gang Liu, Bai-Qing Dong, Yi-Xiang Qin, Xiao-Ling Qin, Shi-Yi Chen, Xiao-Jing Guo, Li Gan, Ruo-Lan Xu, Hai Li, Jing Li
Introduction Tuberculosis (TB) poses a serious challenge to global health systems. The altered intestinal microbiota is associated with the pathogenesis of TB, but the exact links remain unclear. Methods 16 S rDNA sequencing was performed to comprehensively detect the changes in the intestinal microbiota of feces from active TB (ATB), latent TB infection (LTBI) and healthy controls (HC). Results The
-
The PPE2 protein of Mycobacterium tuberculosis is secreted during infection and facilitates mycobacterial survival inside the host Tuberculosis (IF 3.2) Pub Date : 2023-10-12 Manoj Kumar Bisht, Ravi Pal, Priyanka Dahiya, Saba Naz, Priyadarshini Sanyal, Vinay Kumar Nandicoori, Sudip Ghosh, Sangita Mukhopadhyay
Mycobacterium tuberculosis secrets various effector proteins to evade host immune responses for facilitating its intracellular survival. The bacterial genome encodes several unique PE/PPE family proteins, which have been implicated to play important role in mycobacterial pathogenesis. A member of this family, PPE2 have been shown to contain a monopartite nuclear localization signal (NLS) and a DNA
-
Optimizing the formulation variables for encapsulation of linezolid into polycaprolactone inhalable microspheres using double emulsion solvent evaporation Tuberculosis (IF 3.2) Pub Date : 2023-10-05 Yuwanshi Sharma, Riya Mahar, Arpita Chakraborty, Nidhi Nainwal
Inhaled antibiotics delivered through dry powder inhalers (DPIs) effectively treat severe bacterial infections by directly targeting the lungs. Our study focused on developing inhalable dry powder microspheres of linezolid (LNZ) using biodegradable polycaprolactone (PCL) polymer. The LNZ-PCL microspheres were fabricated using a double emulsification solvent evaporation method. Optimization of formulation
-
Exploring COX-2 inhibitors in tuberculosis: A whole-blood model approach for immune response and adjunt therapy evaluation Tuberculosis (IF 3.2) Pub Date : 2023-10-04 Claudia Carranza, Luis G. Sartillo-Mendoza, Laura E. Carreto-Binaghi, Marcela Muñoz-Torrico, Silvia Guzmán-Beltrán, Martha Torres, Yolanda Gonzalez, Esmeralda Juárez
Pulmonary tuberculosis (TB) inflammation is an underestimated disease complication which anti-inflammatory drugs may alleviate. This study explored the potential use of the COX-2 inhibitors acetylsalicylic acid (ASA) and celecoxib in 12 TB patients and 12 healthy controls using a whole-blood ex vivo model where TNFα, PGE2, and LTB4 plasma levels were quantitated by ELISA; we also measured COX-2, 5-LOX
-
Low performance of interferon gamma release assay Quantiferon-TB gold coupled or not with Pst1/3/lipoglycan humoral detection to predict Mycobacterium tuberculosis complex disease in a low-burden area Tuberculosis (IF 3.2) Pub Date : 2023-10-05 Silvia Martinez-Rivera, Helene Guet-Revillet, Fabrice Herin, Guillaume Martin-Blondel, Marcel Miedouge, Laura Billon, Emmanuel Treiner, Yves Renaudineau
Whole T cell interferon gamma release assays such as QuantiFERON-TB Gold Plus (QTF-TB) are used to evaluate Mycobacterium tuberculosis complex (MTC) exposure but fail to discriminate latent tuberculosis infection (LTBI) from active disease. In this study conducted in a low-burden area, 1215 patients presenting MTC risk and tested both for QTF-TB and mycobacterial infection (microscopy, culture, and/or
-
The expression of Nramp1 modulates the uptake of Mycobacterium tuberculosis by macrophages through alternating inflammatory responses Tuberculosis (IF 3.2) Pub Date : 2023-10-02 Chaoqun Meng, Guangxin Chen, Da Wen, Li Dong, Xiaogang Cui, Xuejiao Jing, Jia Cui, Yuanting Gao, Yue Liu, Hongli Bu, Changxin Wu
Natural-resistance-associated macrophage protein-1 (NRAMP1) is a transmembrane protein of the mammalian SLC11 gene family. Previously, genome-wide association study (GWAS) have shown that the single nucleotide polymorphisms (SNPs) of NRAMP1 are associated with human susceptibility to tuberculosis (TB), and the detection of clinical samples have demonstrated that the expression levels of NRAMP1 are
-
In vitro antimycobacterial activity and interaction profiles of diarylthiourea-copper (II) complexes with antitubercular drugs against Mycobacterium tuberculosis isolates Tuberculosis (IF 3.2) Pub Date : 2023-09-25 Anna Bielenica, Agnieszka Głogowska, Ewa Augustynowicz- Kopeć, Jolanta Orzelska-Górka, Dagmara Kurpios-Piec, Marta Struga
The activity of several halogenated copper (II) complexes of 4-chloro-3-nitrophenylthiourea derivatives has been tested against Mycobacterium tuberculosis strains and strains of non-tuberculous mycobacteria. The compounds were 2–16 times more potent than current TB-drugs against multidrug-resistant M. tuberculosis 210. The 3,4-dichlorophenylthiourea complex (5) was equipotent to ethambutol (EMB) towards
-
Clinical performance of nucleotide MALDI-TOF-MS in the rapid diagnosis of pulmonary tuberculosis and drug resistance Tuberculosis (IF 3.2) Pub Date : 2023-09-21 Yuyuan Wang, Qinghua Xu, Bailan Xu, Yichuan Lin, Xia Yang, Jingfeng Tong, Chengchen Huang
Objective To evaluate the application value of nucleotide matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) technology in the rapid diagnosis of pulmonary tuberculosis (PTB) and its drug resistance. Methods From February 2021 to January 2022, respiratory specimens from 214 suspected PTB patients at the First Hospital of Quanzhou were collected. Nucleotide MALDI-TOF-MS
-
Type I interferons and Mycobacterium tuberculosis whole cell lysate induce distinct transcriptional responses in M. tuberculosis infection Tuberculosis (IF 3.2) Pub Date : 2023-09-13 Florence Mutua, Ruey-Chyi Su, Christine Mesa, Carmen Lopez, T. Blake Ball, Sandra Kiazyk
Type I interferon (IFN)-induced genes have the potential for distinguishing active tuberculosis (ATB) from latent TB infection (LTBI) and healthy controls (HC), monitoring treatment, and detection of individuals at risk of progression to active disease. We examined the differential effects of IFN-α, IFN-β and Mycobacterium tuberculosis whole cell lysate (Mtb WCL) stimulation on the expression of selected
-
Mycobacterium bovis BCG dodecin gene codes a functional protein despite of a start codon mutation Tuberculosis (IF 3.2) Pub Date : 2023-09-01 Marcos Gustavo Araujo Schwarz, Paloma Rezende Correa, Paula Silva Lacerda Almeida, Leila Mendonça-Lima
Dodecin is a dodecamer involved in flavin homeostasis, with interesting temperature and osmolarity endurance features in Mycobacterium tuberculosis. A single nucleotide polymorphism in the gene's start codon in BCG, converting ATG to ACG, is predicted to generate a N-terminal shorter isoform, lacking the first 7 amino acids. We previously reported that the shortened recombinant protein has reduced
-
Leprosy: The age-old companion of humans – Re-evaluation and comparative analysis of Avar-period cases with Hansen's disease from the Danube-Tisza Interfluve, Hungary Tuberculosis (IF 3.2) Pub Date : 2023-09-01 Olga Spekker, Balázs Tihanyi, Luca Kis, Ágota Madai, György Pálfi, Réka Csuvár-Andrási, Erika Wicker, Csaba Szalontai, Levente Samu, István Koncz, Antónia Marcsik, Erika Molnár
In recent years, our knowledge of leprosy in the past has substantially been enriched. Nonetheless, much still remains to be discovered, especially in regions and periods from where no written sources are available. To fill in some research gaps, we provide the comparative analysis of eight Avar-period leprosy cases from the Danube-Tisza Interfluve (Hungary). In every case, to reconstruct the biological
-
Predictive biomarkers for latent Mycobacterium tuberculosis infection Tuberculosis (IF 3.2) Pub Date : 2023-08-24 Harinder Singh, Norberto Gonzalez-Juarbe, Rembert Pieper, Yanbao Yu, Sanjay Vashee
Tuberculosis is a leading cause of infectious death worldwide, with almost a fourth of the world's population latently infected with its causative agent, Mycobacterium tuberculosis. Current diagnostic methods are insufficient to differentiate between healthy and latently infected populations. Here, we used a machine learning approach to analyze publicly available proteomic data from saliva and serum
-
Exploring the role of the protein tyrosine kinase a (PtkA) in mycobacterial intracellular survival Tuberculosis (IF 3.2) Pub Date : 2023-08-24 Swati Jaiswal, Satyendra Kumar, Erandi Velarde de la Cruz
Mycobacterium tuberculosis (Mtb) continues to define new paradigms of host-pathogen interaction. There are several host proteins known which are regulated by Mtb infection. The proteins which regulate host biological processes like apoptosis, cell processes, stress proteins, metabolic enzymes, etc. are targeted by the pathogens. Mtb proteins interact directly or indirectly with host proteins and play
-
Comparison of Xpert MTB/RIF Ultra with Xpert MTB/RIF for the detection of Mycobacterium tuberculosis and rifampicin resistance in a primary-level clinic in rural China Tuberculosis (IF 3.2) Pub Date : 2023-08-15 Meng Li, Yong Qiu, Mingcheng Guo, Rong Qu, Fajun Tian, Gengsheng Wang, Ya Wang, Jian Ma, Siyuan Liu, Howard Takiff, Yi-Wei Tang, Qian Gao
The Xpert MTB/RIF Ultra (Ultra) is not yet used for the diagnosis of tuberculosis (TB) in China. We compared the performance of the Xpert and Ultra for detecting Mycobacterium tuberculosis and rifampicin resistance in a primary-level clinic in rural China. Sputum samples from suspected pulmonary TB patients were collected and subjected to smear microscopy, liquid culture, Xpert and Ultra tests. We
-
Toxin-Antitoxin system of Mycobacterium tuberculosis: Roles beyond stress sensor and growth regulator Tuberculosis (IF 3.2) Pub Date : 2023-08-17 Saima khan, Firoz Ahmad, Mohd Ikram Ansari, Mohammad Ashfaque, Mohammad Hayatul Islam, Mohd Khubaib
The advent of effective drug regimen and BCG vaccine has significantly decreased the rate of morbidity and mortality of TB. However, lengthy treatment and slower recovery rate, as well as reactivation of the disease with the emergence of multi-drug, extensively-drug, and totally-drug resistance strains, pose a serious concern. The complexities associated are due to the highly evolved and complex nature
-
Phylactic role of anti-lipoarabinomannan IgM directed against mannan core during mycobacterial infection in macrophages Tuberculosis (IF 3.2) Pub Date : 2023-08-01 Hitoshi Nakayama, Kei Hanafusa, Toshiyuki Yamaji, Eriko Oshima, Tomomi Hotta, Kenji Takamori, Hideoki Ogawa, Kazuhisa Iwabuchi
Mycobacteria enter host phagocytes, such as macrophages by binding to several receptors on phagocytes. Several mycobacterial species, including Mycobacterium tuberculosis have evolved systems to evade host bactericidal pathways. Lipoarabinomannan (LAM) is an essential mycobacterial molecule for both binding to phagocytes and escaping from bactericidal pathways. Integrin CD11b plays critical roles as
-
Deferiprone-gallium-protoporphyrin (IX): A promising treatment modality against Mycobacterium abscessus Tuberculosis (IF 3.2) Pub Date : 2023-07-24 Sholeh Feizi, Muhammed Awad, Roshan Nepal, Clare M. Cooksley, Alkis J. Psaltis, Peter-John Wormald, Sarah Vreugde
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) caused by Mycobacterium abscessus is a frequent complication in patients with cystic fibrosis (CF) that worsens lung function over time. Currently, there is no cure for NTM-PD, hence new therapies are urgently required. Disrupting bacterial iron uptake pathways using gallium-protoporphyrin (IX) (GaPP), a heme analog, has been proposed as a novel
-
The Many Hosts of Mycobacteria 9 (MHM9): A conference report Tuberculosis (IF 3.2) Pub Date : 2023-07-23 Abigail Marie Klever, Kathleen A. Alexander, Deepak Almeida, Matthew Z. Anderson, Ray L. Ball, Gillian Beamer, Paola Boggiatto, Jane E. Buikstra, Bruce Chandler, Tiffany A. Claeys, Aislinn E. Concha, Paul J. Converse, Keith M. Derbyshire, Karen M. Dobos, Kathryn M. Dupnik, Janice J. Endsley, Mark A. Endsley, Kevin Fennelly, Carlos Franco-Paredes, Deanna A. Hagge, Richard T. Robinson
The Many Hosts of Mycobacteria (MHM) meeting series brings together basic scientists, clinicians and veterinarians to promote robust discussion and dissemination of recent advances in our knowledge of numerous mycobacterial diseases, including human and bovine tuberculosis (TB), nontuberculous mycobacteria (NTM) infection, Hansen's disease (leprosy), Buruli ulcer and Johne's disease. The 9th MHM conference
-
Mycobacterium tuberculosis complex whole-genome sequencing in New York State: Implementation of a reduced phenotypic drug susceptibility testing algorithm Tuberculosis (IF 3.2) Pub Date : 2023-07-22 Joseph Shea, Tanya A. Halse, Herns Modestil, Cheryl Kearns, Randal C. Fowler, Cherry-Ann Da Costa-Carter, Ulrike Siemetzki-Kapoor, Melissa Leisner, Pascal Lapierre, Donna Kohlerschmidt, Marie-Claire Rowlinson, Vincent Escuyer, Kimberlee A. Musser
Whole-genome sequencing (WGS) can predict drug resistance and antimicrobial susceptibility in Mycobacterium tuberculosis complex (MTBC) and has shown promise in partially replacing culture-based phenotypic drug susceptibility testing (pDST). We performed a two-year side by side study comparing the prediction of drug resistance and antimicrobial susceptibility by WGS molecular DST (mDST) to pDST to
-
Determining the diagnostic potential of Truenat MTB Plus for Tubercular lymphadenitis and detection of drug resistance and a comparison with GeneXpert Ultra Tuberculosis (IF 3.2) Pub Date : 2023-07-17 Kusum Sharma, Megha Sharma, Nalini Gupta, Tanish Modi, Himanshu Joshi, Ritu Shree, Aman Sharma
Setting Tubercular lymphadenitis (TBLA), the most common form of extrapulmonary tuberculosis, is a diagnostic challenge. Objective Truenat MTB Plus (TruPlus) along with Truenat Rif assay (TruRif) was evaluated for detection of TBLA and rifampicin resistance and compared with GeneXpert Ultra (Xpert Ultra). Design 100 fine-needle aspirated specimens [50 confirmed by culture/smear/cytology, 20 clinically
-
-
Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility Tuberculosis (IF 3.2) Pub Date : 2023-07-05 Rinu Mary Xavier, S.M. Sharumathi, Arun Kanniyappan Parthasarathy, Deepalakshmi Mani, Tharani Mohanasundaram
Therapeutic drug monitoring (TDM) is recommended for medications with high inter-individual variability, narrow therapeutic index drugs, possible drug-drug interactions, drug toxicity, and subtherapeutic concentrations, as well as to assess noncompliance. The area under the plasma concentration-time curve (AUC) is a significant pharmacokinetic parameter since it calculates the drug's total systematic
-
SecretoMyc, a web-based database on mycobacteria secreted proteins and structure-based homology identification using bio-informatics tools Tuberculosis (IF 3.2) Pub Date : 2023-07-06 Jérôme Gracy, Katherine Vallejos-Sanchez, Martin Cohen-Gonsaud
To better understand the interaction between the host and the Mycobacterium tuberculosis pathogen, it is critical to identify its potential secreted proteins. While various experimental methods have been successful in identifying proteins under specific culture conditions, they have not provided a comprehensive characterisation of the secreted proteome. We utilized a combination of bioinformatics servers
-
Evaluation of Mycobacterium tuberculosis derived cell-free DNA using pleural fluid and paired plasma samples for the diagnosis of pleural tuberculosis Tuberculosis (IF 3.2) Pub Date : 2023-07-08 Pratibha Sharma, Rakesh Kumar Gupta, Divya Anthwal, Manisha Dass, Rakesh Yadav, Ashish Behera, Sunil Sethi, Ritu Singhal, Sahajal Dhooria, Ashutosh Nath Aggarwal, Sagarika Haldar
Pleural tuberculosis (pTB) is a grave clinical challenge. A novel cell-free M. tuberculosis DNA (cfM.tb-DNA) probe-based-qPCR assay was developed for the diagnosis of pTB. Total cell-free DNA was extracted from pleural fluid (PF) and paired plasma samples and cfM.tb-DNA was quantified by probe-based qPCR targeting devR (109-bp) gene of M. tuberculosis in patients with pleural effusion. Patient categorization
-
Treatment of tuberculous meningitis: Overdue for concerted action Tuberculosis (IF 3.2) Pub Date : 2023-06-30 Robert J. Wilkinson, Joseph Donovan, Guy E. Thwaites, Reinout van Crevel, Sean Wasserman
Abstract not available